DEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 28, 2022 in Centessa Lawsuit – CNTA

Nov 25th, 2022 10:42 EST

New York, New York--(Newsfile Corp. - November 25, 2022) - Levi & Korsinsky, LLP notifies investors in Centessa Pharmaceuticals plc ("Centessa" or the "Company") (NASDAQ: CNTA) of a class action securities lawsuit.

The lawsuit on behalf of Centessa investors has been commenced in the the United States District Court for the Central District of California. This lawsuit is on behalf of a class consisting of persons and entities that purchased or otherwise acquired: (a) Centessa American Depositary Shares pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about May 28, 2021; and/or (b) Centessa securities between May 28, 2021 and June 1, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=34054&wire=5

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this video? Visit:https://www.youtube.com/watch?v=ac-wggjcO2Y

Centessa Pharmaceuticals plc NEWS - CNTA NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company's product, lixivaptan, was less safe than defendants had represented; (ii) defendants overstated lixivaptan's clinical and commercial prospects; (iii) another Centessa product, ZF874, was less safe than defendants had represented; (iv) defendants overstated ZF874's clinical and commercial prospects while downplaying the drug's safety issues; and (v) as a result, documents issued in connection with Centessa's initial public offering and the Company's public statements throughout the class period were materially false and/or misleading and failed to state information required to be stated therein.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Centessa during the relevant timeframe, you have until November 28, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/centessa-pharmaceuticals-loss-submission-form?prid=34054&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.55 Broadway, 10th FloorNew York, NY 10006[email protected]Tel: (212) 363-7500Fax: (212) 363-7171www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/145759

SHARE

You must be logged in to post a comment.

Related Recent Publications

You must be logged in to post a comment.

Email newsletter

Receive the latest stock news and signals